Piper Sandler initiated coverage of Sarepta with an Overweight rating and $157 price target. The analyst likes the prospects for Elevidys to receive an expanded Duchenne muscular dystrophy label on its FDA action date of June 21.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta to replace ShockWave Medical in S&P 400 at open on 6/3
- Airbnb upgraded, Southwest downgraded: Wall Street’s top analyst calls
- RBC downgrades Sarepta on growing expectations into Elevidys decision
- Sarepta downgraded to Sector Perform from Outperform at RBC Capital
- 3 Best Stocks to Buy Now, 5/23/2024, According to Top Analysts